177Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of life
Purpose The safety and efficacy of 177 Lu-DOTATATE in older patients with advanced neuroendocrine tumours (NET) are not well understood. Methods Patients ≥70 years of age and treated with 177 Lu-DOTATATE were included. Toxicity, health-related quality of life (HRQoL), objective response, progression...
Gespeichert in:
Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2021-10, Vol.48 (11), p.3582-3594 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
The safety and efficacy of
177
Lu-DOTATATE in older patients with advanced neuroendocrine tumours (NET) are not well understood.
Methods
Patients ≥70 years of age and treated with
177
Lu-DOTATATE were included. Toxicity, health-related quality of life (HRQoL), objective response, progression-free survival (PFS) and overall survival (OS) were assessed. The relationship between baseline characteristics and PFS and OS was analysed using the Kaplan-Meier method. Univariate analyses were performed using the Cox proportional hazards model.
Results
In total, 71 patients were included (76.1% midgut primary). The median age at diagnosis and age at
177
Lu-DOTATATE treatment were 70 and 74 years, respectively. The majority (78.9%) of patients completed 4 cycles of
177
Lu-DOTATATE. Clinically significant myelosuppression was rare (2.8%). There was no deterioration in HRQoL and ‘disease-specific worries’ significantly improved (
P
= 0.029). Radiological response assessment was available in 66 patients. Partial response, stable disease and progression of disease were found in 10 (15.2%), 52 (78.8%) and 4 patients (6.1%), respectively. Median PFS and OS were 36.0 and 47.0 months, respectively. Increased baseline alkaline phosphatase was associated with poorer PFS (
P
= 0.002) and OS (
P
= 0.006).
Conclusion
Patients ≥70 years of age with advanced NET treated with
177
Lu-DOTATATE have efficacy and toxicity profiles similar to the wider NET population, without deterioration of HRQoL. |
---|---|
ISSN: | 1619-7070 1619-7089 |
DOI: | 10.1007/s00259-021-05332-0 |